CD274 and cancer: These ICIs have become the most widely used cancer immunotherapies owing to their approval by the United States Food and Drug Administration (U.S. FDA) starting in 2014 for PD-1 ICIs and 2016 for PD-L1 ICIs, and their demonstrated efficacy in a variety of cancers [51,52].